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Abstract 
Introduction: Opsoclonus-myoclonus syndrome (OMS) is an inflammatory neurological dis-
order, often requiring a prompt medical evaluation. Among the diverse etiologies associated 
with OMS are autoimmune, infectious, paraneoplastic, and systemic diseases, and drug intox-
ication. Clinical Summary: The case of a 36-year-old female with a disabling holocranial head-
ache, sudden loss of consciousness, aggressive behavior, vertigo, and a personal history of 
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somatoform disorder and major depression is presented here. After hospital admission, the 
patient developed sudden stereotyped movements in all four extremities and oculogyric crises 
compatible with OMS. Cerebrospinal fluid analysis, viral and autoimmune assays, as well as 
blood, urine, and bronchial secretion cultures, drug metabolite urinalysis, and tumor markers 
were all negative. Furthermore, brain computed tomography (CT) and brain magnetic reso-
nance imaging, along with thoraco-abdominopelvic CT and electroencephalography, were also 
all negative. The patient suffered type one respiratory insufficiency after 72 h of hospitalization, 
requiring an endotracheal tube. After 13 days the patient suffered cardiac arrest. Necropsy was 
performed reporting lymph nodes with a poorly differentiated malignant neoplastic lesion, 
HMB-45, melan-A, vimentin, and S-100 positive, compatible with melanoma metastasis from 
an occult primary cancer. Discussion: While the incidence of melanoma of unknown primary 
is between 2.6 and 3.2%, with a median overall survival ranging between 24 and 127 months, 
when melanoma patients develop OMS their survival is markedly decreased. Although only 5 
cases of paraneoplastic OMS secondary to melanoma have been reported in the literature, all 
had a poor prognosis, dying within 8 months of OMS onset. © 2019 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
Opsoclonus-myoclonus syndrome (OMS) is an inflammatory neurological disorder, often 
requiring an expedient medical evaluation. OMS is also known as opsoclonus-myoclonus-
ataxia or myoclonic encephalopathy and as Kinsbourne syndrome when it affects infants and 
young children [1]. OMS is a rare disease characterized by multidirectional eye movements 
(i.e., saccades) that are involuntary, arrhythmic, and chaotic [2]. These saccades have different 
directional components (i.e., horizontal, vertical, and torsional) and are associated with myo-
clonic limb and trunk sudden movements, cerebellar ataxia, tremor, and encephalopathy [2]. 
Definitive diagnosis for myoclonus is expensive and time-consuming; furthermore, only a mi-
nority of the cases are thoroughly diagnosed [3]. The clinical approach to myoclonus diagnosis 
involves electrophysiological, imaging, and laboratory tests [3]. Among the etiologies associ-
ated with myoclonus are infectious, autoimmune, medications and toxic agents, parane-
oplastic, central nervous system lesions, metabolic diseases, and prion disease [3]. 
We present the clinicopathological case of a patient with sudden stereotyped movements 
in all four extremities and oculogyric crises compatible with OMS. After infectious and post-
infectious etiologies were excluded the patient was screened for autoimmune and drug-re-
lated etiologies, without success. The patient was screened for a neoplastic process through 
imaging and tumor makers, but the results were still negative. After an axillary lymph node 
biopsy, the diagnosis of melanoma was established. Paraneoplastic OMS secondary to mela-
noma is a very rare presentation and prompt tumor diagnosis is needed in order to provide 
adequate care for the patient based on their prognosis and overall survival. 
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A 36-year-old female arrived at the Emergency Department presenting a sudden loss of 
consciousness secondary to head trauma after falling from her own height on two episodes. 
After the second fall, the patient had loss of strength in the lower extremities leading to im-
paired ambulation. The patient had a sudden-onset disabling holocranial headache, aggres-
sive behavior, and vertigo for the 2 weeks prior to her arrival at the Emergency Department. 
The patient did not have any symptoms related to an acute infectious process (e.g., fever or 
malaise). She sought out medical attention at a regional psychiatric hospital from which she 
was referred to our institution with a somatoform disorder and depressive episode diagnosis. 
The patient’s family history included a father deceased secondary to type 2 diabetes and colon 
cancer complications; no other relevant aspects of family history were found. The patient de-
nied the use of controlled substances, allergies, past blood transfusions, traveling to regions 
with endemic diseases within the last 3 months, tattoos, and body piercings. The patient had 
three pregnancies, three deliveries, and no cesarean surgeries, without any psychological or 
physiological complications with regard to her past obstetric history. She was diagnosed with 
major depression 18 months prior to admission to this hospital; however, she had no adher-
ence to medical treatment and two previous suicide attempts within this time period. 
Upon initial physical exploration, we found a recumbent patient with freely chosen body 
position, Glasgow coma score of 11 (i.e., eye-opening 4, verbal response 1, motor response 6), 
without focal neurologic deficits or meningeal sings, aware of her environment but with mut-
ism, and without making verbal or eye contact. The patient’s integumentary system was hy-
drated and without alterations. She had horizontal nystagmus associated with oculogyric cri-
ses, while the rest of the head and neck exploration had no alterations. Fundus examination 
was not performed due to the excessive saccadic eye movements. The musculoskeletal explo-
ration revealed stereotyped movements in all four extremities, which had an onset of a couple 
of hours. The patient had normal plantar and other deep tendon reflexes. Cerebellar function 
and muscle strength were not evaluated due to the patient’s lack of cooperation. Upon inspec-
tion, auscultation, and percussion the cardio-respiratory system had no abnormal findings. 
During thoracic palpation, a mass (2 × 2 × 3 cm, petrous consistency, and immobile) in the 
right axillar line was detected. No abnormalities were found on breast examination. Ab-
dominal examination was without alterations. Upon admission, the patient had the following 
vital signs: blood pressure of 94/60 mm Hg; heart rate of 77 bpm; respiratory rate of 20 rpm; 
temperature of 36.5°C; body-weight of 60 kg; height of 158 cm; and BMI of 24.0. 
Clinical Evolution 
The patient was evaluated by the psychiatry department confirming the somatoform dis-
order and depressive episode diagnosis, providing management with olanzapine and ser-
traline. The neurology department evaluated the patient to assess the sudden-onset move-
ment disorder integrating an OMS. Initial diagnosis suspicion was post-viral cerebellar ataxia 
or neuroinfectious disease. Laboratory results at admission are presented in Table 1. A com-
puted tomography (CT) of the brain was performed to assess intra-axial lesions (e.g., hemor-
rhage, ischemia, and tumors) with normal findings. The cerebrospinal fluid analysis was nor-
mal (Table 1). Management with alprazolam and magnesium valproate was initiated to ad-
dress the psychomotor agitation and movement disorder. The urinalysis was compatible with 
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a urinary tract infection (Table 2) which was treated with intravenous ceftriaxone. Blood, 
bronchial secretion, and urine cultures were performed, with all cultures reporting negative 
results. To exclude viral infection or drug use the following tests were requested: antibodies 
for hepatitis B virus, hepatitis C virus, and HIV, as well as urinalysis for benzodiazepines, bar-
biturates, cannabis, cocaine, methamphetamines, and opiates; all results were reported as 
negative (Table 2). Procalcitonin serum levels were 1.67 ng/mL. After an infectious etiology 
was excluded, an electroencephalogram was performed, yielding no epileptogenic or abnor-
mal activity. In search of an autoimmune etiology, the following tests were requested: cyto-
plasmic antineutrophil cytoplasmatic antibodies, perinuclear antineutrophil cytoplasmatic 
antibodies, anti-double-stranded deoxyribonucleic acid, anti-cardiolipin IgG, anti-cardiolipin 
IgM antibody, and anti-N-methyl-D-aspartate receptor, all reported as negative (Table 2).  
Screening for a neoplastic process in the brain, magnetic resonance imaging (Fig. 1a, b) 
was performed, reporting normal results. The following tumor markers were screened and all 
were reported negative: alpha-fetoprotein, human chorionic gonadotropin, CA125, CA153, 
CA19.9, and carcinoembryonic antigen (Table 2). An axillary ganglion biopsy was performed 
reporting a high-grade and poorly differentiated malignancy (Fig. 2a, b). Immunohistochemi-
cal staining with cytokeratin AE1/AE3, CD 45, Cyclin D1, CD 117, smooth muscle actin-alpha, 
and BCL2 were all reported as negative, while staining for HMB-45, melan-A, vimentin, and  
S-100 were positive. The histopathological diagnosis was compatible with melanoma (Fig. 2c–
f). In search of a primary site simple and contrasted thoracic, abdominal, and pelvic CTs were 
performed (Fig. 1c–f). No primary site or apparent lymphadenopathy were identified. The CT 
of the thorax showed lung parenchyma with areas of consolidation and images compatible 
with ground glass opacities and air bronchogram (Fig. 1c, d). To further search for a primary 
site a positron emission tomography (PET) was scheduled. 
Clinical Outcome 
Seventy-two hours after admission, the patient developed type one respiratory insuffi-
ciency (i.e. vital signs: blood pressure of 90/60 mm Hg; heart rate of 120 bpm, respiratory rate 
of 27 rpm, temperature of 39°C; blood gas test arterial pH = 7.3, PaO2 = 50 mm Hg, PaCO2 = 30 
mm Hg, HCO3– = 18 mEq/L, O2 content = 75%, base excess = –6 mmol/L; lactate = 0.9 mmol/L), 
thus requiring invasive artificial airway with an endotracheal tube and admittance to the In-
tensive Care Unit for further test and treatment. The patient had a torpid evolution character-
ized by purulent bronchial secretions, 39°C body temperature and increase in leucocyte count 
(Table 2). The microorganism Acinetobacter baumannii was isolated from the bronchial se-
cretion (i.e. >100,000 colony-forming units/mL). Intravenous colistimethate and meropenem 
were initiated. Due to the septic process, the PET imaging was not performed.  
After 13 days of hospitalization, the patient presented extreme bradycardia (40 BPM), 
progressing to asystole. Advanced life support protocol was initiated and after 20 min without 
reverting the cardiac arrest the patient was pronounced deceased. Necropsy examination was 
performed by two independent pathologists reporting hemorrhagic lesions at the corpus cal-
losum level, multiple paratracheal and perihilar lymph nodes (e.g. sizes ranging from 0.8 × 0.5 
cm and 1.5 × 1.2 cm) (Fig. 3). The histological sections of the axillary, paratracheal and perihi-
lar lymph nodes showed a poorly differentiated malignant neoplastic lesion constituted by 
pleomorphic cells, atypical nuclei with open chromatin, nuclear pseudo-inclusions, and mito-
sis (Fig. 2a, b, 3c, d). Immunohistochemical staining was performed and antibodies for HMB-
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45, melan-A, vimentin, and S-100 were positive (Fig. 2c–f). Both pathologists reached the same 
diagnosis and were unable to identify the primary site. The final diagnosis was melanoma me-
tastasis from an occult primary cancer. 
Discussion 
To the best of the authors’ knowledge, this is the first case reported in the literature in-
volving a paraneoplastic OMS secondary to melanoma metastasis from an occult primary can-
cer and just the fifth case involving melanoma. The first case of paraneoplastic OMS secondary 
to malignant melanoma was described in 1999 by Berger and Mehari [4] (1999), where the 
male patient had a previous history of malignant melanoma (left shoulder) which progressed 
to a recurrent metastatic melanoma with neurological deterioration after 4 months. The sec-
ond case of OMS secondary to melanoma (vaginal melanoma) reported in the literature de-
scribes a female patient that had a sudden onset OMS which progressed to a coma within 2 
weeks [5]. The third case reported in the literature was also a vaginal melanoma with abrupt 
onset of neurological symptoms with rapid neurological deterioration with improvement af-
ter 6 weeks but ultimately succumbing to the disease after 6 months [6]. The fourth case in-
volves a male patient with an advanced malignant melanoma (mucosal melanoma in the nasal 
cavity) who was first diagnosed with a post-infectious OMS but after neurological deteriora-
tion died 8 months after the onset of neurological symptoms [7]. All cases including the one 
reported here have had a poor prognosis, leading to death within 8 months of the movement 
disorder onset. 
This is the first case in the literature of paraneoplastic OMS that was diagnosed through 
the biopsy of a metastatic site in vivo and confirmed through a necropsy. After imaging, sero-
logical, cerebrospinal fluid analysis, and necropsy by two independent pathologists, the pri-
mary site was not identified; thus, a final diagnosis of melanoma metastasis from an occult 
primary cancer was reached. Among the neoplasms of unknown primary origin, differentiated 
adenocarcinoma corresponds to 60%, poorly differentiated to 30%, undifferentiated to 5%, 
and squamous cell carcinoma to 5% [8]. From a histopathologic perspective, the pathologic 
approach to metastases of unknown primary cancer is stepwise and should incorporate the 
clinical context, morphology, and immunohistochemistry [9]. Primary tumor site prediction 
can be assisted by the diagnosis of malignancy and broad tumor typing (i.e., into carcinoma, 
melanoma, lymphoma, or sarcoma) of an occult primary neoplasm [9]. In a study evaluating 
over 132 thousand patients with melanoma, the incidence of melanoma of unknown primary 
(MUP) was 3.2%, with a median overall survival ranging between 24 and 127 months, a  
5-year survival rate between 28.6 and 75.6%, and a 10-year survival rate between 18.8 and 
62.9% for patients having lymph node metastasis [10]. The survival of fewer than 8 months 
in the 5 OMS cases associated with melanoma is markedly less compared with the overall sur-
vival of 24 and 127 months for MUP alone. Another population-based study reported an inci-
dence of 2.6% in a population of over 33 thousand melanoma patients [11]. In this study, the 
authors report that MUP patients with 2 or more involved lymph nodes had slightly worse 
survival than patients with tumor-node-metastasis stage III melanoma of a known primary 
origin [11]. In the clinicopathological case presented above, 6 lymphatic nodes had metastasis, 
thus contributing to the overall poor prognosis. 
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One of the limitations regarding the diagnostic algorithm in the case presented here was 
the lack of PET imaging. This imaging modality was not performed on the patient due to the 
sudden respiratory failure and subsequent septic process. This imaging modality could have 
assisted in detecting a possible primary site; however, even after undergoing necropsy the 
patient’s primary cancer site was still unknown. Electrophysiological testing (i.e., polymyog-
raphy, electromyography, and somatosensory evoked potential) to classify the myoclonus 
were not performed in the patient due to the rapid neurological deterioration and sudden 
respiratory failure. 
Conclusion 
Adult-onset OMS is rare. Paraneoplastic and parainfectious causes are the most com-
monly identified etiologies and should be initially considered in adult-onset OMS [12]. Alt-
hough complete remission in OMS is commonly achieved with immunotherapy, when OMS is 
associated with either melanoma of a known primary origin or MUP the survival is markedly 
reduced [12]. Considering that OMS secondary to melanoma is rare, the available literature 
and this clinicopathological case report suggest that paraneoplastic OMS associated with mel-
anoma has a poor survival. 
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Fig. 1. Brain magnetic resonance imaging (MRI) and thoraco-abdominopelvic computed tomography (CT). 
a Normal axial T2-weighted MRI scan with a thalamic window. b Normal sagittal T1-weighted scan with 
gadolinium with a midbrain window. c CT of the thorax without contrast, mediastinal window, a small area 
of consolidation in both hemithorax with left predominance; this consolidation was accompanied by air 
bronchogram. d CT of the thorax with a lower (basal) plane, where volume asymmetry is observed favoring 
the right hemithorax, as well as bilateral ground-glass opacities with right predominance. e Normal coro-
nal reconstruction of thoraco-abdominopelvic CT with contrast. f Normal sagittal thoraco-abdominopelvic 
CT with contrast. 
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Fig. 2. Histopathology. a Axillary ganglion. Hematoxylin and eosin staining. ×50. High-grade and poorly 
differentiated malignancy. b Axillary ganglion. Hematoxylin and eosin staining. ×100. Poorly differentiated 
malignant neoplastic lesion constituted by pleomorphic cells, atypical nuclei with open chromatin, nuclear 
pseudo-inclusions, and mitosis. c–f Axillary ganglion. ×100. Histopathological diagnosis compatible with 
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Fig. 3. Necropsy of the brain and lungs. Histopathology of paratracheal and perihilar lymph nodes. a Nec-
ropsy of the brain. Coronal brain with hemorrhagic lesions at the corpus callosum level. b Necropsy of the 
lungs. Paratracheal and perihilar lymph nodes with sizes ranging from 0.8 × 0.5 cm to 1.5 × 1.2 cm, firm, 
with solid surface and abundant dark pigment. c Histopathology of paratracheal and perihilar lymph nodes. 
Hematoxylin and eosin staining. ×100. Poorly differentiated malignant neoplastic lesion with nuclear 
pseudo-inclusions and mitosis. d Histopathology of paratracheal and perihilar lymph nodes. Hematoxylin 
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Table 1. Laboratory test results upon admission 
  
  
Full blood count Meningitis/encephalitis PCR assay 
   
   
Hemoglobin at admission, g/dL 13.6 Bacteria 
Hematocrit, % 40.6 Escherichia coli K1 Not detected 
Erythrocyte count, µL 3,600 Haemophilus influenzae Not detected 
Platelet count, µL 1,400 Listeria monocytogenes Not detected 
Mean corpuscular volume, fL 91.2 Neisseria meningitides Not detected 
Mean corpuscular hemoglobin, g/dL 33.6 Streptococcus agalactiae Not detected 
Leukocyte count, µL 8,300 Streptococcus pneumoniae Not detected 
Lymphocytes, % 18.1 Mycobacterium tuberculosis Not detected 
Neutrophils, % 75.5 Viruses 
Monocytes, % 5.9 Cytomegalovirus Not detected 
Eosinophils, % 0.2 Enterovirus Not detected 
Basophils, % 0.3 Herpes simplex virus 1 Not detected 
Blood chemistry Herpes simplex virus 2 Not detected 
Glucose, mg/dL 88 Human herpesvirus 6 Not detected 
Albumin, g/dL 2.42 Human parechovirus Not detected 
Urea nitrogen, mg/dL 0.47 Varicella zozter virus Not detected 
Blood urea nitrogen, mg/dL 12.6 Yeast 
Uric acid, mg/dL 7 Cryptococcus neoformans/gattii Not detected 
Cholesterol, mg/dL 130 Cerebrospinal fluid 
Triglycerides, mg/dL 140 Aspect Rock water 
Liver function enzymes Leucocytes 0 
Aspartate transaminase, U/L 33 Gram staining No bacteria 
Alanine transaminase, U/L 35 Culture No development  
Lactate dehydrogenase, U/L 160   
Albumin, mg/dL 3.3   
Alkaline phosphatase, U/L 100   
Gamma-glutamyl transpeptidase, U/L 10   
Blood coagulation   
Prothrombine time, s 18   
Partial thromboplastin time, s 40   
International normalized ratio 1.36   
Electrolytes   
Sodium, mEq/dL 139   
Potassium, mE/dL 4.7   
Chlorine, mEq/dL 112   
Calcium, mg/dL 9.7   
Phosphorus, mg/dL 4   
Magnesium, mEq/dL 1.29   
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Table 2. Follow-up laboratory test results 
 
 
Full blood count at 13th day of hospitalization 
Platelet count, µL 170,000 
Leukocyte count, µL 17,400 
Neutrophils, % 97 
Lymphocytes, % 2.6 
Monocytes, % 0.4 
Eosinophils, % 0 
Basophils, % 0 
Procalcinotine, ng/mL 8 
  Antibodies 
Cytoplasmic antineutrophil cytoplasmatic antibodies 0.1 
Perinuclear antineutrophil cytoplasmatic antibodies 0.2 
Anti-double-stranded deoxyribonucleic acid, UI/mL 0.9 
Anti-cardiolipin IgG, UI/mL 1.0 
Anti-cardiolipin IgM antibody, UI/mL 3.0 
Anti-N-methyl-D-aspartate receptor Negative  
  Viral panel 
Hepatitis B virus Negative 
Hepatitis C virus Negative 
Human immunodeficiency virus Negative 
  Tumor markers 
Alpha-fetoprotein, IU/mL 1,590 
Human chorionic gonadotropin, mU/mL 0.31 
CA125, UI/mL 34 
CA153, UI/mL  5.4 
CA19.9, UI/mL 7.4 
Carcinoembryonic antigen, ng/mL 1,410 
  Urinalysis 
Appearance Cloudy 
pH 6.0 
Specific gravity 1.032 
Proteins, mg/dL 30 
Ketones, glucose, and nitrite Negative 
Leukocytes (per high power field) 210 
Erythrocytes (per high power field) 400 
Bacteria Abundant 
  
  
 
 
 
